Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Non-Current Assets (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Non-Current Assets for 9 consecutive years, with $22.9 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 47.82% to $22.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $115.2 million through Dec 2025, down 37.51% year-over-year, with the annual reading at $22.9 million for FY2025, 47.82% down from the prior year.
  • Non-Current Assets hit $22.9 million in Q4 2025 for Sutro Biopharma, down from $27.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $122.9 million in Q4 2021 to a low of $22.9 million in Q4 2025.
  • Historically, Non-Current Assets has averaged $58.1 million across 5 years, with a median of $51.7 million in 2023.
  • Biggest five-year swings in Non-Current Assets: surged 708.24% in 2021 and later plummeted 56.23% in 2022.
  • Year by year, Non-Current Assets stood at $122.9 million in 2021, then crashed by 56.23% to $53.8 million in 2022, then decreased by 8.55% to $49.2 million in 2023, then decreased by 10.77% to $43.9 million in 2024, then tumbled by 47.82% to $22.9 million in 2025.
  • Business Quant data shows Non-Current Assets for STRO at $22.9 million in Q4 2025, $27.5 million in Q3 2025, and $30.7 million in Q2 2025.